Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, January 6, 2023
[ Fri, Jan 06th 2023
] - WOPRAI
[ Fri, Jan 06th 2023
] - WOPRAI
[ Fri, Jan 06th 2023
] - WOPRAI
[ Fri, Jan 06th 2023
] - WOPRAI
[ Fri, Jan 06th 2023
] - WOPRAI
[ Fri, Jan 06th 2023
] - WOPRAI
[ Fri, Jan 06th 2023
] - WOPRAI
[ Fri, Jan 06th 2023
] - WOPRAI
[ Fri, Jan 06th 2023
] - WOPRAI
[ Fri, Jan 06th 2023
] - WOPRAI
Thu, January 5, 2023
[ Thu, Jan 05th 2023
] - WOPRAI
[ Thu, Jan 05th 2023
] - WOPRAI
[ Thu, Jan 05th 2023
] - WOPRAI
[ Thu, Jan 05th 2023
] - WOPRAI
[ Thu, Jan 05th 2023
] - WOPRAI
[ Thu, Jan 05th 2023
] - WOPRAI
[ Thu, Jan 05th 2023
] - WOPRAI
[ Thu, Jan 05th 2023
] - WOPRAI
[ Thu, Jan 05th 2023
] - WOPRAI
[ Thu, Jan 05th 2023
] - WOPRAI
[ Thu, Jan 05th 2023
] - WOPRAI
[ Thu, Jan 05th 2023
] - WOPRAI
[ Thu, Jan 05th 2023
] - WOPRAI
[ Thu, Jan 05th 2023
] - WOPRAI
[ Thu, Jan 05th 2023
] - WOPRAI
Geoff Meacham Initiated (AMLX) at Strong Buy and Held Target at $50 on, Jan 5th, 2023
Geoff Meacham of B of A Securities, Initiated "Amylyx Pharmaceuticals, Inc." (AMLX) at Strong Buy and Held Target at $50 on, Jan 5th, 2023.
Geoff has made no other calls on AMLX in the last 4 months.
There are 4 other peers that have a rating on AMLX. Out of the 4 peers that are also analyzing AMLX, 1 agrees with Geoff's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Chris Shibutani of "Goldman Sachs" Maintained at Hold with Increased Target to $40 on, Friday, September 9th, 2022
These are the ratings of the 3 analyists that currently disagree with Geoff
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $50 on, Monday, October 24th, 2022
- Neena Bitritto-Garg of "Citigroup" Maintained at Strong Buy with Increased Target to $50 on, Monday, October 3rd, 2022
- Marc Goodman of "SVB Leerink" Maintained at Buy with Increased Target to $50 on, Thursday, September 8th, 2022
